Patient Satisfaction With Mirena In Patients Aged 35 To 45 With Heavy Menstrual Bleeding Referred To Mardan Medical Complex From Jan 2014 To Dec 2016
Original Article
DOI:
https://doi.org/10.69830/jbkmc.v1i02.58Keywords:
Mirena, Amenorrhea, spotting, satisfaction level, Quality of lifeAbstract
Background: Less blood loss in menstrual cycles builds a woman’s perception of gravity and indicates an influence
on their judgment about treatment success. Many of the world’s women are fed up with undergoing surgery and less
satisfied with the medical treatment of HMB. Mirena provides a non-surgical alternative, which is reversible and
fertility-sparing. The study’s primary aim was to determine the satisfaction level of women using Mirena within the
reproductive age of 35-45 years.
Methods: A total of 50 patients with mirena induction were included in the study. Women less than 35 and above
45 years of age, with a uterus larger than 12 weeks, those with pelvic inflammatory disease, and women with implants
other than Mirena were excluded from the study. The women were inspected for the principal complaints, duration of
complaints, and ultrasound findings. The satisfaction level was assessed for all patients using Mirena with symptoms
controlling, like blood reduction.
Results: The study constituted a total of 50 females ranging from 35 to 45 years old. The majority of them were
aged 35-40 years. The use of the Mirena technique has subsequently not only reduced the heavy menstrual blood loss
but also controlled symptoms like Amenorrhea and spotting. The satisfaction level of the women using it is very high.
These women highly recommended the option to other women.
Conclusion: Mirena is an effective treatment option for HMB among women 35-45. It achieved high satisfaction
of patients after insertion.
Keywords: Mirena, Amenorrhea, spotting, satisfaction level, Quality of life
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Hemasa Gul, Nuzhat Amin, Muhammad Hussain

This work is licensed under a Creative Commons Attribution 4.0 International License.













